These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34003301)

  • 1. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
    Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing soluble immune checkpoint molecules and TGF-β
    Okita R; Senoo T; Mimura-Kimura Y; Mimura Y; Murakami T; Ikeda E; Okada M; Inokawa H; Aoe K
    Sci Rep; 2024 Jul; 14(1):15947. PubMed ID: 38987362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
    Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
    J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.
    Asciak R; Kanellakis NI; Bibby A; Kidd A; Gerry S; Mercer R; Maskell N; Blyth KG; Fsadni P; Montefort S; Psallidas I; Rahman NM
    Chest; 2021 Nov; 160(5):1925-1933. PubMed ID: 34119515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
    Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
    J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
    Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
    Suzuki K; Kadota K; Sima CS; Sadelain M; Rusch VW; Travis WD; Adusumilli PS
    Cancer Immunol Immunother; 2011 Dec; 60(12):1721-8. PubMed ID: 21769693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
    Barsky AR; Ahern CA; Venigalla S; Verma V; Anstadt EJ; Wright CM; Ludmir EB; Berlind CG; Lindsay WD; Grover S; Cengel KA; Simone CB
    Clin Lung Cancer; 2020 Nov; 21(6):e583-e591. PubMed ID: 32611504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
    Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
    Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.
    Urso L; Silic-Benussi M; Boscolo A; Lorenzi M; Bonanno L; Lunardi F; Guarneri V; Calabrese F; Rea F; Conte P; Pasello G
    Cytokine; 2021 Oct; 146():155622. PubMed ID: 34153874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions.
    Okamoto M; Hasegawa Y; Hara T; Hashimoto N; Imaizumi K; Shimokata K; Kawabe T
    Chest; 2005 Dec; 128(6):4030-5. PubMed ID: 16354877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
    Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
    Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
    Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
    Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.